Certified by Founder Lodge
DCVC Bio
United States - Palo Alto, California
INVESTOR
1 Disclosed Funding Rounds $50,000,000
49 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
DCVC Bio is a VC fund investing in early-stage computational biology startups. Advances in genetic sequencing, artificial intelligence and automation are converging to transform existing life
| Company | Date | Round | Raised |
|---|---|---|---|
 CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
 Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
 Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
 Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
 Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 Unlearn.AI |
April, 19 ,2022 | Series B | $50,000,000 |
 Ascend Gene & Cell Therapies |
May, 10 ,2023 | Series A | $132,500,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
| Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| CH4Global |
August, 30 ,2023 | Series B | $29,000,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
 Mainspring Energy |
April, 16 ,2025 | Series F | $258,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Mainspring Energy |
April, 16 ,2025 | Series F | $258,000,000 |
| Mainspring Energy |
April, 16 ,2025 | Series F | $258,000,000 |
 Grove Biopharma, Inc. |
April, 25 ,2025 | Series A | $30,000,000 |
| Latus Bio |
May, 03 ,2024 | Series A | $54,000,000 |
 Alchemab Therapeutics Ltd |
September, 10 ,2025 | Series A | |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
 Nilo Therapeutics |
October, 10 ,2025 | Series A | $101,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
| Mainspring Energy |
April, 16 ,2025 | Series F | $258,000,000 |
| Grove Biopharma, Inc. |
April, 25 ,2025 | Series A | $30,000,000 |
| Alchemab Therapeutics Ltd |
September, 10 ,2025 | Series A | |
| Nilo Therapeutics |
October, 10 ,2025 | Series A | $101,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
